3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Recurrence
2
Sarcoma
1
Neoplasms
1
Multiple Myeloma
1
Lymphoma, B-Cell
1
Burkitt Lymphoma
1
Interventions
Doxorubicin
15
pembrolizumab
12
Cyclophosphamide
9
Surgical Procedures, Operative
8
Gemcitabine
8
Blood Specimen Collection
8
Ifosfamide
7
Surveys and Questionnaires
6
Nivolumab
6
Trabectedin
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Drug Therapy
5
fludarabine
4
Temozolomide
4
Specimen Handling
4
Radiation Dose Hypofractionation
4
Biopsy
4
selinexor
3
pazopanib
3
liposomal doxorubicin
3
cabozantinib
3
atezolizumab
3
anlotinib
3
Radiation
3
Observation
3
Docetaxel
3
Dacarbazine
3
trastuzumab deruxtecan
2
toripalimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Sarcoma
×
Immunoconjugates
×
Clear all
NCT06797999
2026-01-28
ADCElerate1
Adcendo ApS
Phase 1/2
Recruiting
270 enrolled